12/05/2026
The regenerative medicine industry is at a critical crossroads.
On one side: science, transparency, oversight, and patient safety.
On the other: marketing hype, regulatory gray zones, and products making claims they were never approved to make.
We wanted to simplify and share a slide deck that breaks down a difficult but important reality in the U.S. stem cell and exosome space:
• Why IV biologics remain under intense FDA scrutiny
• The difference between living cellular products and lyophilized “powder” products
• How broken supply chains and lack of traceability create patient risk
• Why state laws do not override federal biologics regulations
• And why quality systems, chain of custody, clinical rigor, and transparency matter more now than ever
At Auragens, we believe regenerative medicine has extraordinary potential — but only when approached responsibly, ethically, and with uncompromising standards.
Patients deserve more than promises.
They deserve evidence, oversight, and integrity.
The future of this industry will not be defined by who markets the loudest;
It will be defined by who is willing to operate at the highest level of science, safety, and accountability.